$TNON
Tenon Medical, Inc.

2023 Q2 Form 10-Q Financial Statement

#000157587223000685 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $743.0K $433.0K $71.00K
YoY Change 450.37% 509.86%
Cost Of Revenue $549.0K $480.0K $275.0K
YoY Change 102.58% 74.55%
Gross Profit $194.0K -$47.00K -$204.0K
YoY Change -242.65% -76.96%
Gross Profit Margin 26.11% -10.85% -287.32%
Selling, General & Admin $3.615M $4.005M $1.313M
YoY Change -22.47% 205.03%
% of Gross Profit 1863.4%
Research & Development $901.0K $834.0K $562.0K
YoY Change 37.14% 48.4%
% of Gross Profit 464.43%
Depreciation & Amortization $35.00K $25.00K $10.00K
YoY Change 84.21% 150.0%
% of Gross Profit 18.04%
Operating Expenses $4.516M $4.839M $1.875M
YoY Change -15.11% 158.08%
Operating Profit -$4.322M -$4.886M -$2.079M
YoY Change -20.78% 135.02%
Interest Expense $56.00K -$273.0K
YoY Change -120.51%
% of Operating Profit
Other Income/Expense, Net $37.00K $56.00K -$1.000K
YoY Change -215.63% -5700.0%
Pretax Income -$4.285M -$4.830M -$2.353M
YoY Change -21.92% 105.27%
Income Tax
% Of Pretax Income
Net Earnings -$4.285M -$4.830M -$2.353M
YoY Change -21.92% 105.27%
Net Earnings / Revenue -576.72% -1115.47% -3314.08%
Basic Earnings Per Share -$0.33 -$0.43 -$2.38
Diluted Earnings Per Share -$0.33 -$0.43 -$209.4K
COMMON SHARES
Basic Shares Outstanding 11.25M 11.25M 990.0
Diluted Shares Outstanding 13.05K shares 11.24K 990.0

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.345M $4.916M $4.677M
YoY Change -60.38% 5.11%
Cash & Equivalents $5.852M $3.179M $4.677M
Short-Term Investments $493.0K $1.737M $0.00
Other Short-Term Assets $413.0K $193.0K $82.00K
YoY Change 197.12% 135.37%
Inventory $570.0K $416.0K $602.0K
Prepaid Expenses $413.0K $193.0K
Receivables $601.0K $316.0K $64.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.929M $5.841M $5.425M
YoY Change -52.97% 7.67%
LONG-TERM ASSETS
Property, Plant & Equipment $945.0K $852.0K $1.251M
YoY Change 292.12% -31.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.500M
YoY Change
Other Assets $219.0K $118.0K $469.0K
YoY Change 329.41% -74.84%
Total Long-Term Assets $1.926M $1.788M $1.720M
YoY Change 51.3% 3.95%
TOTAL ASSETS
Total Short-Term Assets $7.929M $5.841M $5.425M
Total Long-Term Assets $1.926M $1.788M $1.720M
Total Assets $9.855M $7.629M $7.145M
YoY Change -45.65% 6.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $912.0K $928.0K $425.0K
YoY Change 164.35% 118.35%
Accrued Expenses $1.130M $530.0K $1.197M
YoY Change -31.8% -55.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.78M
YoY Change
Total Short-Term Liabilities $6.866M $2.752M $15.40M
YoY Change 207.07% -82.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.086M $2.403M $840.0K
YoY Change 166.75% 186.07%
Total Long-Term Liabilities $2.086M $2.403M $840.0K
YoY Change 166.75% 186.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.866M $2.752M $15.40M
Total Long-Term Liabilities $2.086M $2.403M $840.0K
Total Liabilities $8.952M $5.155M $16.24M
YoY Change 196.62% -68.26%
SHAREHOLDERS EQUITY
Retained Earnings -$48.61M -$44.32M
YoY Change 71.06%
Common Stock $22.00K $11.00K
YoY Change 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $903.0K $2.474M -$22.74M
YoY Change
Total Liabilities & Shareholders Equity $9.855M $7.629M $7.145M
YoY Change -45.65% 6.77%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.285M -$4.830M -$2.353M
YoY Change -21.92% 105.27%
Depreciation, Depletion And Amortization $35.00K $25.00K $10.00K
YoY Change 84.21% 150.0%
Cash From Operating Activities -$3.176M -$3.576M -$2.464M
YoY Change 14.95% 45.13%
INVESTING ACTIVITIES
Capital Expenditures $128.0K $84.00K -$128.0K
YoY Change -412.2% -165.63%
Acquisitions
YoY Change
Other Investing Activities $1.257M $4.753M $4.404M
YoY Change -115.44% 7.92%
Cash From Investing Activities $1.129M $4.669M $4.276M
YoY Change -113.8% 9.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.707M -42.00K -54.00K
YoY Change -66.84% -22.22%
NET CHANGE
Cash From Operating Activities -3.176M -3.576M -2.464M
Cash From Investing Activities 1.129M 4.669M 4.276M
Cash From Financing Activities 4.707M -42.00K -54.00K
Net Change In Cash 2.660M 1.050M 1.758M
YoY Change -18.1% -40.27%
FREE CASH FLOW
Cash From Operating Activities -$3.176M -$3.576M -$2.464M
Capital Expenditures $128.0K $84.00K -$128.0K
Free Cash Flow -$3.304M -$3.660M -$2.336M
YoY Change 21.38% 56.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001560293
CY2023Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41364
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
TENON MEDICAL, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5574718
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
104 Cooper Court
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Los Gatos
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95032
CY2023Q1 dei City Area Code
CityAreaCode
408
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
649-5760
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TNON
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11251299
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3179000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2129000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
1737000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
6441000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
316000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
228000
CY2023Q1 us-gaap Inventory Net
InventoryNet
416000
CY2022Q4 us-gaap Inventory Net
InventoryNet
415000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
193000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
134000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
5841000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9347000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
852000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
793000
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
818000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
873000
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
67000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
25000
CY2023Q1 us-gaap Assets
Assets
7629000
CY2022Q4 us-gaap Assets
Assets
11089000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
928000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
550000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
530000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
717000
CY2023Q1 tnon Accrued Commissions Current
AccruedCommissionsCurrent
1059000
CY2022Q4 tnon Accrued Commissions Current
AccruedCommissionsCurrent
1035000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
235000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
228000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2752000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2530000
CY2023Q1 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1781000
CY2022Q4 tnon Accrued Commissions Noncurrent
AccruedCommissionsNoncurrent
1624000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
622000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
683000
CY2023Q1 us-gaap Liabilities
Liabilities
5155000
CY2022Q4 us-gaap Liabilities
Liabilities
4837000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11251299
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11251299
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11236801
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11236801
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46873000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45833000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44322000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39492000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-88000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2474000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6252000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7629000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11089000
CY2023Q1 us-gaap Revenues
Revenues
433000
CY2022Q1 us-gaap Revenues
Revenues
71000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
480000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
275000
CY2023Q1 us-gaap Gross Profit
GrossProfit
-47000
CY2022Q1 us-gaap Gross Profit
GrossProfit
-204000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
834000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
562000
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2026000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
276000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1979000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1037000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4839000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1875000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4886000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2079000
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
56000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
274000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
56000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-274000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4830000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2353000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.38
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.38
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11242
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11242
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
990
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
990
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4830000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2353000
CY2023Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities
13000
CY2022Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Tax Portion Attributable To Parent Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossTaxPortionAttributableToParentAvailableforsaleSecurities
0
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4818000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2353000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6252000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1040000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2474000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-20552000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
169000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-22736000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4830000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2353000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
274000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1040000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
169000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
55000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
51000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
88000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-11000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
414000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
95000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
378000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-51000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-118000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-54000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-48000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3576000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2464000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4753000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4404000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4669000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4276000
CY2023Q1 tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
42000
CY2022Q1 tnon Payments For Deferred Offering Costs
PaymentsForDeferredOfferingCosts
54000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-42000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-54000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1050000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1760000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2129000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2917000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3179000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4677000
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
530000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
717000
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13765000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates</div></div></div><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"> </div><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">accrued commissions, incremental borrowing rate, obsolescence</div> of inventory, stock-based compensation and the fair value of investments, inventory and of the Company’s common stock.</div></div>
CY2023Q1 tnon Percentage Of Valuation Allowance In Deferred Tax Assets
PercentageOfValuationAllowanceInDeferredTaxAssets
1
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2374376
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4391981
CY2021Q2 tnon Lessee Operating Lease Expiration Month And Year
LesseeOperatingLeaseExpirationMonthAndYear
2026-06
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
818000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
873000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
235000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
228000
CY2023Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities
0
CY2022Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion In Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAvailableforsaleSecurities
0
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
56000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
1000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
957000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
873000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
80000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
852000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
793000
CY2023Q1 us-gaap Depreciation
Depreciation
25000
CY2022Q1 us-gaap Depreciation
Depreciation
10000
CY2023Q1 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
321000
CY2022Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
452000
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
209000
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
265000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
622000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
683000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
857000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
911000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
221000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
301000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
310000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
144000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
976000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
119000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
857000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
72000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
70000
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y3M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3937550
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
7000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10487904
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1:2 reverse stock split
CY2022Q2 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
one-to-0.5
CY2022Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
85739
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1040000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
169000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
0
CY2023Q1 tnon Disclosure Of Reconciliation Of Liability
DisclosureOfReconciliationOfLiability
<table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;;margin-right : auto;"><tr><td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; border-top: none; border-bottom: none; padding: 0px 0px 0.375pt; vertical-align: bottom; width: 87%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal; text-align: center;"> </div></td><td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0in 0in 0.375pt; vertical-align: bottom;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; text-align: center; margin-right: 0px;"> </div></td><td colspan="2" style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0in; vertical-align: bottom; white-space: nowrap; width: 11%; border-bottom: 0.75pt solid black;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="white-space: nowrap;;font-weight:bold;display:inline;">2023</div></div></div></td><td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0in 0in 0.375pt; vertical-align: bottom; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; line-height: normal; white-space: nowrap; margin-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: none; border-bottom: none; padding: 0px; vertical-align: bottom; width: 87%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Balance at <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">December 3</div>1, 2022</div></div><div style="margin-top: 1em"/></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; margin-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; border-bottom: none; border-top: 0px solid windowtext; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: none; padding: 0in; vertical-align: bottom; width: 10%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; margin-right: 0px; line-height: normal; white-space: nowrap;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,560</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="background: rgba(255, 255, 255, 0); border-top: none; border-bottom: none; padding: 0px; vertical-align: bottom; width: 87%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amounts paid during 2023</div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in; vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; margin-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in; vertical-align: bottom; width: 1%; border-bottom: none; border-top: none; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; line-height: normal; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgba(255, 255, 255, 0); border-top: none; border-bottom: none; padding: 0in; vertical-align: bottom; width: 10%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; margin-right: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">(77</div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-top: 0in none; border-bottom: none; padding: 0px 0px 1pt; vertical-align: bottom; width: 87%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accretion</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; margin-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding-top: 0in; padding-right: 0in; padding-left: 0in; vertical-align: bottom; width: 1%; text-align: left; border-bottom: 2pt solid black;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; line-height: normal; text-indent: 0in; text-align: left; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding-top: 0in; padding-right: 0in; padding-left: 0in; vertical-align: bottom; width: 10%; white-space: nowrap; text-align: right; border-bottom: 2pt solid black;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; margin-right: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">204</div></div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr><tr><td style="background: rgba(255, 255, 255, 0); border-top: none; border-bottom: none; padding: 0px 0px 1.25pt 10pt; vertical-align: bottom; width: 87%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Balance at March 31, 2023</div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal; margin-right: 0px;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in; vertical-align: bottom; width: 1%; border-bottom: 2.5pt double windowtext; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">$</div></div></td><td style="background: rgba(255, 255, 255, 0); border-bottom: 2.5pt double windowtext; padding: 0in; vertical-align: bottom; width: 10%; white-space: nowrap; text-align: right;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: right; margin-right: 0px; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">2,687</div></div></td><td style="background: rgba(255, 255, 255, 0); padding: 0in 0in 1.25pt; vertical-align: bottom; width: 1%; white-space: nowrap; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; margin: 0px 0px 0px 0in; text-align: left; line-height: normal; white-space: nowrap; text-indent: 0in;"><div style="font-family: &quot;Times New Roman&quot;, Times, &quot;serif&quot;; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"> </div></div></td></tr></table>

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001575872-23-000685-index-headers.html Edgar Link pending
0001575872-23-000685-index.html Edgar Link pending
0001575872-23-000685.txt Edgar Link pending
0001575872-23-000685-xbrl.zip Edgar Link pending
cm305_ex31-1.htm Edgar Link pending
cm305_ex31-2.htm Edgar Link pending
cm305_ex32-1.htm Edgar Link pending
cm305_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnon-20230331.htm Edgar Link pending
tnon-20230331.xsd Edgar Link pending
tnon-20230331_cal.xml Edgar Link unprocessable
tnon-20230331_lab.xml Edgar Link unprocessable
tnon-20230331_pre.xml Edgar Link unprocessable
tnon-20230331_def.xml Edgar Link unprocessable
tnon-20230331_htm.xml Edgar Link completed